TREATMENT FOR RELAPSING PLATINUM SENSITIVE EPITHELIAL OVARIAN CANCER
|
|
- Eleanor Hines
- 5 years ago
- Views:
Transcription
1 TREATMENT FOR RELAPSING PLATINUM SENSITIVE EPITHELIAL OVARIAN CANCER Sandro Pignata, MD, PhD Sabrina Chiara Cecere, MD Uro-Gynecological Department, Division of Medical Oncology, IRCCS National Cancer Institute Fondazione G. Pascale, Naples, Italy
2 OVARIAN CANCER (OC) RELAPSE Despite the best upfront treatment, ovarian cancer has a high incidence of relapse About 70 80% of FIGO stage III-IV ovarian cancer patients develop a disease relapse within 5 years Yang JC, et al. N Engl J Med. 2003; 349: Adapted from: Piccart MJ, et al. Randomised Intergroup Trial of Cisplatin Paclitaxel Versus Cisplatin Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results, J Natl Cancer Inst, 2000, 92, 9, , by permission of Oxford University Press
3 RECURRENT OVARIAN CANCER (ROC): POPULATION CHARACTERISTICS Response to Platinum Time to Recurrence Response to Further Platinum Platinum-sensitive 12 mos 30-60% Platinum-partially sensitive 6-12 mos 25-30% Platinum-resistant <6 mos <10% Platinum-refractory No initial response N/A
4 THE PLATINUM-FREE INTERVAL (PFI) TO CLASSIFY OC RELAPSE Breaking the old and arbitrary categorisation of relapsed OC P R I M A R Y T H E R A P Y Refractory Resistant Partially Sensitive Fully Sensitive months Pisano C, et al. Ther Clin Risk Manag. 2009;5: ; Gadducci A, et al. Anticancer Res. 2001;21:
5 Survival (days) Response rate (%) THE PLATINUM-FREE INTERVAL (PFI) TO CLASSIFY OC RELAPSE Breaking the old and arbitrary categorisation of relapsed OC Overall survival Response rate /Pr TFI (months) PFS Platinum sensitivity is a continous variable Adapted from Pujade-Lauraine E, et al. Proc Am Soc Clin Oncol. 2002;21: Abstract 829.
6 PFI IS NOT THE ONLY FACTOR TO CONSIDER IN THE TREATMENT CHOICE Fifth Ovarian Cancer Consensus Conference of the Gynaecologic Cancer InterGroup: recurrent disease From the Tokyo GCIG OC consensus conference PFI revisited Wilson MK, et al. Ann Oncol 2017;2(4): Treatment-free Interval (TFI) vs. Platinum-free Interval (PFI) Leary AF, et al. Ann Oncol Apr 1;28(4):
7 «ONE SIZE DOSE DOES NOT FIT ALL» Breaking the old and arbitrary categorisation of relapsed OC Comorbidities Performance status Residual toxicities Symptoms gbrca Patient Tumour Histology Molecular characterisation sbrca HRD status (?) Surgery Previous treatments (type, number) Target maintenance therapy TFI Availability of treatments Treatment
8 Fifth Ovarian Cancer Consensus Conference of the Gynaecologic Cancer InterGroup: recurrent disease What has to be considered for platinum-sensitive relapse: Is there a role for surgery at relapse? Is a platinum-based therapy an option? Wilson MK, et al. Ann Oncol 2017;2(4):727 32
9 Fifth Ovarian Cancer Consensus Conference of the Gynaecologic Cancer InterGroup: recurrent disease What has to be considered for platinum-sensitive relapse: The role of surgery at relapse Non platinum-based therapy as an option Platinum-based therapy as an option Wilson MK, et al. Ann Oncol 2017;2(4):727 32
10 PLATINUM-SENSITIVE OC RELAPSE AGO DESKTOP III (ENGOT-ov20; NCT ): Surgery at relapse Study Design 80 centres in 12 countries Recruitment 9/2010 3/ of 409 pts evaluated (2 screening failures) Patients with: 1 st relapse PSROC AGO Score +ve R Cytoreductive surgery with max. effort for complete resection n=408 No OP PFS by Surgical Outcome Platinum-based combination therapy strongly recommended Immediate platinum-based combination therapy strongly recommended OP allowed 3 rd line Median PFS (mos) ΔPFS (mos) HR (95% CI) P-value Wald-test No surgery Surgery but with residual tumour ( ) Surgery with complete resection ( ) < du Bois A, et al. J Clin Oncol 35, 2017 (suppl; abstract 5501). Presented at ASCO Annual Meeting Courtesy of Prof A. du Bois.
11 PLATINUM-SENSITIVE OC RELAPSE Surgery at relapse: The new reality GOG-0213 trial design Women with recurrent ovarian, peritoneal primary or fallopian tube cancer and a treatment free interval 6 months Surgical candidate YES N=107 NO N=567 R Surgery No surgery R Regimen I Carboplatin AUC 5 Paclitaxel 175 mg/m 2 q 21 days n=674 Regimen II Carboplatin AUC 5 Paclitaxel 175 mg/m 2 Bevacizumab 15 mg/kg q 21 days Maintenance Bevacizumab 15 mg/kg q 21 days until progression or toxicity precludes further treatment Coleman L, et al. J Clin Oncol 36, 2018 (suppl; abstr 5501). Presented at ASCO Annual Meeting 2018.
12 PLATINUM-SENSITIVE OC RELAPSE Surgery at relapse: The new reality Coleman L, et al. J Clin Oncol 36, 2018 (suppl; abstr 5501). Presented at ASCO Annual Meeting Courtesy of Prof L. Coleman.
13 Fifth Ovarian Cancer Consensus Conference of the Gynaecologic Cancer InterGroup: recurrent disease What has to be considered for platinum-sensitive relapse: The role of surgery at relapse Non platinum-based therapy as an option Platinum-based therapy as an option Wilson MK, et al. Ann Oncol 2017;2(4):727 32
14 WHEN PLATINUM IS NOT AN OPTION Platinum hypersensitivity Progressed or relapsed OC during last platinum Residual toxicity (e.g. neurotoxicity, ) Wilson MK, et al. Ann Oncol 2017;2(4):727 32
15 WHEN PLATINUM IS NOT AN OPTION Hypersensitivity, incidence and development Incidence seems to be correlated with increased number of cycles of carboplatin administered, occurring in less than 1% of the patients during primary treatment but in 8 44% of patients during 2 nd or 3 rd line 1,2 The risk of hypersensitivity reactions rises with a longer platinum-free interval 3 Particular caution is advised in patients receiving: 4 More than eight courses of carboplatin Second platinum dose after reintroduction in second-line chemotherapy 1. Sliesoraitis S, Chikhale PJ. Int J Gynecol Cancer. 2005;15:13-8; 2. Gadducci A, et al. Int J Gynecol Cancer. 2008;18(4):615-20; 3. O Cearbhaill R, et al. Gynecol Oncol. 2011;116(3):326-31; 4. Markman M, et al. J Clin Oncol.1999;17(4):
16 WHEN PLATINUM IS NOT AN OPTION: TFIP 6 12 MONTHS OVA-301 trial An open-label, multi-centre, randomised Phase 3 study comparing the combination of PLD and Trabectedin with PLD alone in patients with advanced relapsed ovarian cancer (ROC) PFS 1 OS 2,3 1. Poveda A, et al. Ann Oncol 2011;22(1):39 48, by permission of Oxford University Press on behalf of the European Society for Medical Oncology (ESMO) ; 2. Reprinted from Eur J Cancer, 2012; 48, Monk BJ, et al. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis, ; Copyright 2012, with permission from Elsevier. 3. Poveda A, et al. Cancer Treat Rev 2014;40:
17 WHEN PLATINUM IS NOT AN OPTION The post hoc analysis of the OVA-301 trial: TFIP 6-12 months T+PLD a valid option in BRCA mutated ROC BRCA1-mutated patients treated with T+PLD showed longer PFS and OS compared to PLD BRCA1 mut may predict improved outcome to T + PLD treatment Monk BJ, et al. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study. Ann Oncol 2015;26(5): by permission of Oxford University Press on behalf of The European Society for Medical Oncology (ESMO).
18 Fifth Ovarian Cancer Consensus Conference of the Gynaecologic Cancer InterGroup: recurrent disease What has to be considered for platinum-sensitive relapse: The role of surgery at relapse Non platinum-based therapy as an option Platinum-based therapy as an option Wilson MK, et al. Ann Oncol 2017;2(4):727 32
19 WHEN PLATINUM IS AN OPTION Platinum-based combination Platinum-based combination PARP inhibitors Carboplatin + gemcitabine + bevacizumab bevacizumab maintenance (for bevacizumab naïve) Platinum-based combination + bevacizumab bevacizumab maintenance (for bevacizumab pre-treated in first line)
20 WHEN PLATINUM IS AN OPTION Platinum-based combination Platinum-based combination PARP inhibitors Carboplatin + gemcitabine + bevacizumab bevacizumab maintenance (for bevacizumab naïve) Platinum-based combination + bevacizumab bevacizumab maintenance (for bevacizumab pre-treated in first line)
21 WHEN PLATINUM IS AN OPTION All the platinum based combinations are equivalent in terms of efficacy, with different toxicity profiles ICON 4/AGO OV 2.2 GEICO 0104 CARBO AUC5 + TAX 175 mg/m² q21d Alopecia, neurotoxicity, haematologic toxicity, hypersensibility AGO OV 2.5 CARBO AUC4 d1+ GEM 1000 mg/m² d1,8 q21d Haematologic toxicity, hypersensibility CALYPSO/ AGO OV 2.9 CARBO AUC5 + PLD 30 mg/m² Palmoplantar erythrodysesthesia, mucositis, thrombocytopenia
22 META-ANALYSIS COMBINATION THERAPY VS. MONOTHERAPY Carbo/paclitaxel, carbo/pld, carbo/gemcitabine Endpoint Odds ratio combo/mono (95% CI) P value ORR (n=1730, 8 studies) 1.42 ( ) PFS at 2 years (n=2234, 7 studies) 0.67 ( ) PFS at 1 year 0.69 ( ) OS at 2 years (n=2315, 8 studies) 0.80 ( ) 0.012* Combination chemotherapy appears to improve ORR, PFS, and OS when compared to monotherapy in the management of ROC Orlando M, et al. ASCO 2007, Abstract 5524; Pfisterer J, et al. J Clin Oncol. 24: , 2006; Parmar MK, et al. Lancet 361: , 2003.
23 WHEN PLATINUM IS AN OPTION Platinum-based combination Platinum-based combination PARP inhibitors Carboplatin + Gemcitabine + bevacizumab bevacizumab maintenance (for bevacizumab naïve) platinum-based combination + bevacizumab bevacizumab maintenance (for bevacizumab pre-treated in first line)
24 SOLO2/ENGOT-OV21: STUDY DESIGN Patients BRCA1/2 mutation Platinum-sensitive relapsed ovarian cancer At least 2 prior lines of platinum therapy CR or PR to most recent platinum therapy R 2:1 Olaparib tablets 300 mg bid n=196 Placebo n=99 Primary endpoint Investigator-assessed PFS Sensitivity analysis: PFS by blinded independent central review (BICR) Key secondary endpoints: Time to first subsequent therapy or death (TFST), time to second progression (PFS2), time to second subsequent therapy or death (TSST), overall survival (OS) Safety, health-related quality of life (HRQoL*) *Primary endpoint for HRQoL was trial outcome index (TOI) of the FACT-O (Functional Assessment of Cancer Therapy Ovarian) Presented by Pujade-Lauraine E, at SGO 2017 Annual Meeting.
25 Progression-free survival (%) PFS BY INVESTIGATOR ASSESSMENT Olaparib (n=196) Placebo (n=99) Events (%) 107 (54.6) 80 (80.8) Median PFS, months Months since randomisation Median follow-up was 22.1 months in the olaparib group and 22.2 months for placebo Reprinted from The Lancet Oncol, 18(9), Pujade-Lauraine E, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial, Copyright 2017, with permission from Elsevier.
26 NOVA STUDY Phase III trial of maintenance therapy with Niraparib in recurrent platinum-sensitive high-grade serous ovarian cancer Patient stratification Relapsed high-grade serous histology or known gbrca mut 2 prior regimens of platinum-based chemotherapy Responded to last platinum regimen; remains in response and enrolled within 8 weeks of completion of last platinum regimen No measurable lesion >2 cm Non-gBRCA mut gbrca mut Time to disease progression on penultimate platinum-based therapy Bevacizumab with last or penultimate chemotherapy CR/PR during last platinum regimen Mirza MR, et al. N Engl J Med 2016;375: N=553 R 2:1 R 2:1 Niraparib 300 mg QD N=234 Placebo N=116 Niraparib 300 mg QD N=138 Placebo N=65 Primary endpoint BICR-assessed PFS in 3 predefined cohorts gbrca Overall Non-gBRCA Non-gBRCA HRD+ Key secondary endpoints PRO, chemotherapy-free interval; time to first subsequent treatment; PFS2; time to second subsequent treatment; OS; safety Exploratory analysis Non-gBRCA mut cohort: PFS stratified by HRD/BRCA status HRD positive, sbrca mut HRD-positive BRCA wt HRD-negative
27 NOVA TRIAL: MAINTENANCE NIRAPARIB IN PLATINUM-SENSITIVE HGOC 1º Endpoint: BICR assessed PFS Niraparib (n=138) Placebo (n=65) Median PFS, months HR= % CI 0.17, 0.41 P<0.001 Niraparib (n=234) Placebo (n=116) Median PFS, months HR= % CI 0.34, 0.61 P<0.001 From N Engl J Med, Mirza MR, et al, Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer, 375, Copyright 2016, Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
28 Progression-free survival (%) Progression-free survival (%) Progression-free survival (%) NOVA EXPLORATORY ANALYSIS PFS in non-gbrca mut subgroups HRD positive HRD negative sbrca mut (n=47) BRCA wt (n=115) (n=134) Niraparib (n=35) Placebo (n=12) Niraparib (n=71) Placebo (n=44) Niraparib (n=92) Placebo (n=42) PFS median (95% CI) (Months) 20.9 (9.7 NR) 11.0 (2.0 NR) PFS median (95% CI) (Months) 9.3 ( ) 3.7 ( ) PFS median (95% CI) (Months) 6.9 ( ) 3.8 ( ) Hazard ratio (95% CI); P value 0.27 ( ); P= Hazard ratio (95% CI); P value 0.38 ( ); P= Hazard ratio (95% CI); P value 0.58 ( ); P= % of patients without progression or death at 12 mo 62% 19% % of patients without progression or death at 12 mo 45% 11% % of patients without progression or death at 12 mo 27% 7% % of patients without progression or death at 18 mo 52% 19% % of patients without progression or death at 18 mo 27% 6% % of patients without progression or death at 18 mo 19% 7% Hazard ratio 0.27 (95% CI ) P= Hazard ratio 0.38 (95% CI ) P< Hazard ratio 0.58 (95% CI ) P=0.02 Niraparib Placebo No. at Risk Months since randomisation Niraparib Placebo Niraparib Niraparib Placebo Placebo No. at Risk No. at Risk Months since randomisation Months since randomisation Niraparib Niraparib Placebo Placebo From N Engl J Med, Mirza MR, et al., Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer, 375, Copyright 2016, Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society; Mirza MR, et al. Ann Oncol. 2016;27(Suppl 6): Abstract LBA3_PR.
29 ARIEL-3 Phase 3, randomised, double-blind study of rucaparib vs. placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma study design Patient eligibility Stratification High-grade serous or endometrioid epithelial OC, primary peritoneal, or fallopian tube cancers Sensitive to penultimate platinum Responding to most recent platinum (CR or PR)* Excludes patients without assessable disease following second surgery CA-125 within normal range No restriction on size of residual tumour ECOG PS 1 No prior PARP inhibitors R 2:1 HRR gene mutation status by NGS analysis: BRCA1 or BRCA2 Non-BRCA HRR gene None of the above Response to recent platinum CR PR Progression-free interval after penultimate platinum 6 to 12 months >12 months Rucaparib 600 mg BID n=375 Placebo BID n=189 *CR (defined by RECIST) or PR (defined by RECIST and/or a GCIG CA-125 response [CA-125 within normal range]) maintained until entry to ARIEL3 ( 8 weeks of last dose of chemotherapy). ATM, ATR, ATRX, BARD1, BLM, BRIP1, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RPA1.,BID.
30 ARIEL3 Investigator-Assessed Progression-Free Survival BRCA mutant Median HRD Median ITT Rucaparib (n=130) Placebo (n=66) (months) 95% CI HR, 0.23; 95% CI, ; P< Rucaparib (n=236) Placebo (n=118) (months) 95% CI HR, 0.32; 95% CI, ; P< Rucaparib (n=375) Placebo (n=189) Median (months) 95% CI HR, 0.36; 95% CI, ; P< At risk (events) Rucaparib 130 (0) 93 (23) 63 (46) 35 (58) 15 (64) 3 (67) 0 (67) Placebo 66 (0) 24 (37) 6 (53) 3 (55) 1 (56) 0 (56) Rucaparib, 48% censored Placebo, 15% censored At risk (events) Rucaparib 236 (0) 161 (55) 96 (104) 54 (122) 21 (129) 5 (134) 0 (134) Placebo 118 (0) 40 (68) 11 (95) 6 (98) 1 (101) 0 (101) Rucaparib, 43% censored Placebo, 14% censored Rucaparib 375 (0) 228 (111) At risk (events) 128 (186) 65 (217) 26 (226) 5 (234) 0 (234) Placebo 189 (0) 63 (114) 13 (160) 7 (164) 2 (167) 1 (167) 0 (167) Rucaparib, 38% censored Placebo, 12% censored Reprinted from The Lancet, Vol.390, Nº10106, Coleman RL, et al., The Lancet,, Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial, p Copyright 2017, with permission from Elsevier.
31 WHEN PLATINUM IS AN OPTION Platinum-based combination Platinum-based combination PARP inhibitors Carboplatin + gemcitabine + bevacizumab bevacizumab maintenance (for bevacizumab naïve) Platinum-based combination + bevacizumab bevacizumab maintenance (for bevacizumab pre-treated in first line)
32 WHEN PLATINUM IS AN OPTION Bevacizumab in platinum-sensitive relapsed OC: the OCEANS trial CBDCA AUC 4 GEM 1000 mg/m 2 d1, 8 Platinum-sensitive recurrent OC Measurable disease ECOG 0/1 No prior chemo for recurrent OC No prior bevacizumab n=484 CG + placebo CG + bevacizumab Placebo q3w until progression CBDCA AUC 4 GEM 1000 mg/m 2 d1, 8 Bevacizumab 15 mg/kg q3w until progression Stratification variables: Platinum-free interval (6-12 vs. >12 months) Cytoreductive surgery for recurrent disease (yes vs. no) CG for 6 (up to 10) cycles Epithelial ovarian, primary peritoneal, or fallopian tube cancer. Aghajanian C, et al. J Clin Oncol 30(17), 2012:
33 WHEN PLATINUM IS AN OPTION OCEANS trial: PFS and OS results Primary analysis of PFS 1 Final OS 2 1. Aghajanian C, et al. J Clin Oncol, 30(17), 2012: Reprinted with permission American Society of Clinical Oncology; 2. Reprinted from Gynecol Oncol 139(1), Aghajanian C, et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer, Copyright 2015, with permission from Elsevier.
34 WHEN PLATINUM IS AN OPTION Platinum-based combination Platinum-based combination PARP inhibitors Carboplatin + gemcitabine + bevacizumab bevacizumab maintenance (for bevacizumab naïve) Platinum-based combination + bevacizumab bevacizumab maintenance (for bevacizumab pre-treated in first line)
35 x6-8 cycles WHEN PLATINUM IS AN OPTION Bevacizumab beyond progression in platinum-sensitive bevacizumab pre-treated relapsed OC: the MITO-16/MaNGO OV-2 trial design CG + placebo Carboplatin PLD or gemcitabine or paclitaxel Stage IIIB-IV EOC, FT or PPC progressing or recurring at least 6 months after front-line chemotherapy plus avastin (n 400) 1:1 Carboplatin PLD or gemcitabine or paclitaxel CG + bevacizumab Avastin 15 mg/kg q3w Primary endpoint PFS Until PD
36 WHEN PLATINUM IS AN OPTION MITO-16B/MaNGO OV-2B trial: PFS results PFS Investigator assessed (Primary endpoint) Standard Experimental Log Rank P No. of events Median PFS 8.8 months 11.8 months <0.001 HR* (95% CI) 0.51 ( ) *Adjusted by: Age, PS, centre size, bevacizumab at relapse, chemo backbone, residual disease at initial surgery Pignata S, et al. J Clin Oncol 36, 2018 (suppl; abstr 5506). Presented at ASCO Annual Meeting 2018.
37 WHEN PLATINUM IS AN OPTION Treatment algorithm BRCA mutated or WT Platinum based treatment Radiologic CR or PR Olaparib/ niraparib Platinum based ct If TFIp 6-12 months consider Pld + trabectedin Platinum based treatment Carbo-gem + bevacizumab Bevacizumab Platinum based treatment Olaparib/ niraparib TFIp 6-12 months Pld + trabectedin Platinum based ct SECOND LINE MAINTENANCE THIRD LINE FOURTH LINE
38 CONCLUSIONS Platinum free interval is not the only parameter to be considered to select treatment for recurrence. Other parameters including biology, pathology and previous target maintenance therapy need to be taken into account. Recurrent OC patients are classified for being candidate or not to a platinum re-treatment. Indication for surgery must be assessed although final results of trials are still pending. Platinum combination chemotherapy is more effective than single agent platinum. In patients who respond to a platinum based therapy, PARP-i maintenance is effective in prolonging PFS, with higher effect in BRCA mutated patients. Platinum based therapy plus bevacizumab prolongs PFS compared to chemo alone, both in patients who are bevacizumab naive or bevacizumab pre-treated. Bev-containing regimens given in preference to patients at high risk of quick progression and large bulk of disease. In patients with TFI between 6 12 months, not candidate for platinum, trabectedine-pld should be considered.
39 THANK YOU!
A New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG
A New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG Arizona Oncology (US Oncology Network) Professor, Gynecologic Oncology University of Arizona and Creighton
More informationESMO SUMMIT AFRICA. Latest evidence and current standard of care in advanced ovarian cancer. C.Sessa. Cape Town February 2018
ESMO SUMMIT AFRICA Latest evidence and current standard of care in advanced ovarian cancer C.Sessa IOSI, Bellinzona, CH Cape Town 14-16 February 2018 CONFLICT OF INTEREST DISCLOSURE None Ovarian carcinoma
More informationTrabectedina + PLD nel trattamento del carcinoma ovarico. Nicoletta Colombo Universita Milano Bicocca Istituto Europeo Oncologia Milano
Trabectedina + PLD nel trattamento del carcinoma ovarico Nicoletta Colombo Universita Milano Bicocca Istituto Europeo Oncologia Milano The old definition of Recurrent Ovarian Cancer P R I M A R Y T H E
More informationThe OReO Study. Study design & Protocol Study design Key Inclusion criteria Patient population Recruitment and retention tools
The OReO Study A Phase IIIb, Randomised, Double-blind, Placebo-controlled, multi-centre Study of Olaparib Maintenance Re-treatment in Patients with Epithelial Ovarian Cancer Previously treated with a and
More informationInhibidores de PARP en cáncer de ovario
Inhibidores de PARP en cáncer de ovario Ma Pilar Barretina Ginesta Servicio Oncología Médica Hospital Universitari Dr. J. Trueta Institut Català d Oncologia Coordinación científica: Dr. Fernando Rivera
More informationControversies in the Management of Advanced Ovarian Cancer
안녕하세요 Controversies in the Management of Advanced Ovarian Cancer Mansoor R. Mirza Nordic Society of Gynaecological Oncology (NSGO) & Rigshospitalet Copenhagen University Hospital, Denmark Primary Debulking
More informationOvarian Cancer: New insights into biology and treatment
Ovarian Cancer: New insights into biology and treatment 2018 Master Class Course Ursula A. Matulonis, MD Director, Gynecologic Oncology Brock-Wilson Family Chair Dana-Farber Cancer Institute Professor
More informationTRUST Trial on Radical Upfront Surgical Therapy
AGO OP.7 / TRUST TRUST Trial on Radical Upfront Surgical Therapy A close international cooperation ENGOT ov33 Ongoing Trials status update AGO-OVAR OP.7 / TRUST ENGOT-ov33 Trial setting: Sponsor: Pt with
More informationFoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
More informationMedicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático
Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático Dra. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau. Barcelona Introduction Ovarian cancer is the fifth
More informationCurrent Medical Oncology Approaches to Gynecologic Cancers. Mihaela Cristea, MD Associate Professor Medical Oncology
Current Medical Oncology Approaches to Gynecologic Cancers Mihaela Cristea, MD Associate Professor Medical Oncology Nothing to disclose DISCLOSURE Ovarian Cancer Objectives: a. To discuss new FDA approved
More informationPractical Guidance and Strategies for PARP Inhibition. Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy
Practical Guidance and Strategies for PARP Inhibition Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy Clinical Data Maintenance therapy : BRCA-mutated or all
More informationSOLO-1. Dott.ssa Elisabetta Sanna U.O.C. Ginecologia Oncologica- AOB Cagliari Direttore: Dott. Antonio Macciò
SOLO-1 maintenance therapy in patients with newly diagnosed advanced ovarian cancer following platinum-based chemotherapy Dott.ssa Elisabetta Sanna U.O.C. Ginecologia Oncologica- AOB Cagliari Direttore:
More informationTarceva Trial EORTC 55041
Tarceva Trial EORTC 55041 Primary Chemotherapy Tarceva consolidation 2 years Control Patients closed / 835 Leading Participating EORTC AGO-AUSTRIA, ANZGOG, GINECO, MRC/NCIC, MANGO Randomised trial on Erlotinib
More informationCurrent GCIG Trials in Ovarian Cancer
Lead Grou p Log Current GCIG Trials in Ovarian Cancer Andres Poveda, MD GCIG Chair PARSGO Marrakech April 2018 History of GCIG Collaboration 1992 Collaboration on two studies of paclitaxel in ovarian cancer
More informationDr. Josep M. Del Campo Clínica Diagonal. Barcelona
Dr. Josep M. Del Campo Clínica Diagonal. Barcelona Nuevas Oportunidades en Cáncer de Ovario Cancer de Ovario: Es una enfermedad única? Cáncer de Ovario: Tratamiento actual Tratamiento inicial: sin cambios
More informationGOG-172: Survival Outcomes
CHEMOTHERAPY GOG-172: Survival Outcomes Progression-Free Survival Overall Survival Proportion Progression-Free 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 Rx Group IV IP PF Failed Total 50 160 210 63 142
More informationESMO SUMMIT MIDDLE EAST 2018
ESMO SUMMIT MIDDLE EAST 2018 Practice changing studies in Gynecological Cancer in 2017 Dr Susana Banerjee MBBS MA PhD FRCP Consultant Medical Oncologist and Research Lead Gynaecology Unit The Royal Marsden
More informationThe Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology
The Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology April 26, 2013 Larry J. Copeland M.D. Thank You for Your Friendship! 1982 1996 2013 The Ohio State University
More informationGOG212: Taxane Maintenance
GOG212: Taxane Maintenance Epithelial Ovarian or Primary Peritoneal Cancer Optimal or Suboptimal Cytoreduction Clinical C with normal CA125, no symptoms, normal CT Primary Carboplatin and Paclitaxel (or
More informationLate recurrent epithelial ovarian cancer
Late recurrent epithelial ovarian cancer Dominic Richards University of Cape Town and New Somerset Hospital Gynaecological Oncology Unit September 2016 LATE RECURRENT EPITHELIAL OVARIAN CANCER Background
More informationACRIN Gynecologic Committee
ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationJemal A, Siegel R, Ward E, et al: Cancer statistics, CA: Cancer J Clin 59(4):225-49, 2009
Ovarian cancer 2010-22,500 cases diagnosed per year in the United States and 16,500 deaths per year1. - Most patients are diagnosed in late stages; no screening test exists. - Pathology: 4 different types
More informationUpdate on PARP inhibitors: opportunities and challenges in cancer therapy
Update on PARP inhibitors: opportunities and challenges in cancer therapy Vanda Salutari Unità di Ginecologia Oncologica Fondazione Policlinico Universitario A. Gemelli vanda.salutari@policlinicogemelli.it
More informationVirtual Journal Club. Ovarian Cancer. Reference Slides. Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies
Virtual Journal Club Ovarian Cancer Reference Slides Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies Mansoor R. Mirza, MD Copenhagen University Hospital Rigshospitalet
More informationDrug Niraparib Olaparib
Dear NCCN Value Pathway Committee, We are making this submission to provide information that we believe is relevant for developing NCCN Categories of Preference for the use of PARP inhibitors in recurrent
More informationGynecologic Oncology Unit IRCCS Istituto Tumori Milano G. Maltese. Milan - Italy
Gynecologic Oncology Unit IRCCS Istituto Tumori Milano G. Maltese Milan - Italy Mutations typically associated with ovarian carcinoma subtypes High-grade serous ovarian cancer TP53: encodes a protein that
More informationClinical Trials. Ovarian Cancer
1.0 0.8 0.6 0.4 0.2 0.0 < 65 years old 65 years old Events Censored Total 128 56 184 73 35 108 0 12 24 36 48 60 72 84 27-10-2012 Ovarian Cancer Stuart M. Lichtman, MD Attending Physician 65+ Clinical Geriatric
More informationThe Role of PARP Inhibitors in Ovarian Cancer: An Emerging Picture
The Role of PARP Inhibitors in Ovarian Cancer: An Emerging Picture This satellite symposium took place on 10 th September 2017 as part of the European Society for Medical Oncology (ESMO) Congress in Madrid,
More informationNCCN Guidelines for Ovarian Cancer V Meeting on 11/15/17
OV-1 External request: Submission from Vermillion/ASPiRA Laboratories to consider: Inclusion of the following recommendation in the workup for suspected ovarian cancer: OVA1 and/or Multivariate Index Assay
More informationPARP Inhibitors: Patients Selection. Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016
PARP Inhibitors: Patients Selection Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016 OVARIAN CANCER (OC): MULTIPLES DISEASES Different types with different behaviour
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationCurrent state of upfront treatment for newly diagnosed advanced ovarian cancer
Current state of upfront treatment for newly diagnosed advanced ovarian cancer Ursula Matulonis, M.D. Associate Professor of Medicine, HMS Program Leader, Medical Gyn Oncology Dana-Farber Cancer Institute
More informationSurgery in Recurrent Ovarian Cancer - an emerging area of evidence -
Surgery in Recurrent Ovarian Cancer - an emerging area of evidence - Andreas du Bois Kliniken Essen Mitte (KEM), Germany AdB 2018 A long and winding road to define the role of surgery in relapsed OC called
More informationCómo Incorporar la Terapia Antiangiogénica en el Cáncer de Ovario? XIV Congreso Nacional Salamanca Octubre de 2013 SESION CONTROVERSIA-1 15,45-17H
Cómo Incorporar la Terapia Antiangiogénica en el Cáncer de Ovario? XIV Congreso Nacional Salamanca Octubre de 2013 SESION CONTROVERSIA-1 15,45-17H Andres Poveda Fundación Instituto Valenciano de Oncología
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationOvarian Cancer: Implications for the Pharmacist
Ovarian Cancer: Implications for the Pharmacist Megan May, Pharm.D., BCOP Objectives Describe the etiology and pathophysiology of ovarian cancer Outline the efficacy and safety of treatment options for
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationRicombinazione omologa nel carcinoma ovarico: BRCA e oltre. F. Raspagliesi MD
Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre F. Raspagliesi MD raspagliesi@istitutotumori.mi.it BRCA molecular signature in ovarian cancer In a pooled analysis of 26 observational studies
More informationPROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC
PROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC Giorgia Mangili RUF ginecologia oncologica medica IRCCS San Raffaele Milano mangili.giorgia@hsr.it STANDARD CHEMOTHERAPY The standard chemotherapy
More informationCANCER DE L OVAIRE EN RECHUTE. Eric Pujade-Lauraine Hôpital Hôtel-Dieu Paris, France
CANCER DE L OVAIRE EN RECHUTE Eric Pujade-Lauraine Hôpital Hôtel-Dieu Paris, France When to treat? CA 125 definition of progression agreed by GCIG Doubling of CA 125 level from normal upper limit or from
More informationTable Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies
Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Uterus Study N Eligibility Regimen RR (No. of Responses) Median OS Grade 3/4 Toxicities Nimeiri et al[42] Total:
More informationTreatment of Recurrent Ovarian Cancer
Treatment of Recurrent Ovarian Cancer Mihaela Cristea, MD Associate Professor Medical Oncology, City of Hope November 11, 2016 No disclosures Financial Disclosure Epithelial Ovarian Cancer Subtypes and
More informationSide Effects. PFS (months) Study Regimen No. patients. OS (months)
Study Regimen No. patients PFS (months) OS (months) Side Effects Phase II PR ov ca 1 Phase II GOG PR+PS ov ca 1 Bev (15 mg/kg) q3wks Bev (15 mg/kg) q3wks 44 4.4 10.7 HTN, Proteinuria, GI perf (11%) stopped
More informationCo-Chairs Helen J MacKay and Diane Provencher On behalf of the OV21/PETROC Investigators CCTG, NCRI (UK), GEICO and SWOG
OV21/PETROC: A Randomized Gynecologic Cancer Intergroup (GCIG) Phase II Study of Intraperitoneal (IP) vs. Intravenous (IV) Chemotherapy Following Neoadjuvant Chemotherapy and Optimal Debulking Surgery
More informationCarcinosarcoma Trial rial in s a in rare malign rare mali ancy
Carcinosarcoma Trials in a rare malignancy BACKGROUND Rare and highly aggressive epithelial malignancies Biphasic tumors with epithelial and mesenchymal components Uterine carcinomas (UCS) uncommon with
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationIntraperitoneal chemotherapy: where are we going? A. Gadducci Pisa
Intraperitoneal chemotherapy: where are we going? A. Gadducci Pisa Intraperitoneal Chemotherapy (IP) in advanced ovarian cancer (EOC): Rationale The spread of disease is often limited to the peritoneal
More informationMITO Phase III TRIALS. May 2009
MITO Phase III TRIALS Sandro Pignata MD PhD May 2009 Liposomal doxorubicin stealth vs carboplatin/paclitaxel in recurrent ovarian cancer patients with platinumfree interval between 6-12 months MITO 8 ENGOT
More informationNordic Society of Gynaecological Oncology
Nordic Society of Gynaecological Oncology - from a Nordic interest group to a global leader in clinical trials Line Bjørge 14. mars 2017 I 1 Profile NSGO is a non-political, non-profit society Nordic platform
More informationBreakfast with Professor Advances in ovarian cancer first-line treatment : The role of anti angiogenics
Breakfast with Professor Advances in ovarian cancer first-line treatment : The role of anti angiogenics CLAUDIO CALAZAN Oncologia D Or Oncologistas Associados First-line treatment : The role of anti angiogenics
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationAngiogenesis in Ovarian Cancer
Angiogenesis in Ovarian Cancer Dr Shibani Nicum Consultant Medical Oncologist and Lead for Gynae- Oncology Oxford University Hospitals Content 1. Epithelial Ovarian Cancer : epidemiology 2. Angiogenesis-normal
More informationClinical Data With PARP Inhibitors in Ovarian Cancer
Clinical Data With PARP Inhibitors in Ovarian Cancer Thomas J. Herzog, MD, FACOG, FACS Paul & Carolyn Flory Professor Clinical Director, University of CincinnaD Cancer InsDtute CincinnaD, OH Clinical Data
More informationSafety Findings From FORWARD II: A Phase Ib Study Evaluating the Folate Receptor Alpha (FR
Safety Findings From FORWARD II: A Phase Ib Study Evaluating the Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC) Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab,
More informationESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY
ESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY LUGANO, MAY 4-5, 2018 Clinical development in ovarian cancer C. Sessa, CH CONTENT Rationale for immunotherapy in ovarian cancer Clinical data with single agent immune
More informationNew Treatments for Early Ovarian Cancer. Jonathan Ledermann UCL Cancer Institute University College London
New Treatments for Early Ovarian Cancer Jonathan Ledermann UCL Cancer Institute University College London Lucerne Oct 213 Progression-free survival in first-line trials of platinum-based chemotherapy 1998
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationCERVICAL/VULVAR CANCER CLINICAL TRIALS
CERVICAL/VULVAR CANCER CLINICAL TRIALS ALL-COMERS Primary Treatment Locally Advanced Recurrent Cervical GTFB (07-0935) TISSUE BANK ALL GYN TISSUE ETCTN (Phase II) (17-0458) LAO-MD017/#10010 Phase II Study
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationNew targets in endometrial and ovarian cancer
New targets in endometrial and ovarian cancer SAMO Interdisciplinary Workshop on Gynecologic Tumors Luzern, January 16-17, 2016 C. Sessa IOSI Bellinzona Outline New targets in ovarian cancer - Cell cycle
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,350 108,000 1.7 M Open access books available International authors and editors Downloads Our
More informationResidual Tumor Following Surgery: The Strongest Prognostic Factor or a Myth? Philipp Harter, MD Kliniken Essen Mitte Essen, Germany
Residual Tumor Following Surgery: The Strongest Prognostic Factor or a Myth? Philipp Harter, MD Kliniken Essen Mitte Essen, Germany What Are Our Questions Q1: Prognostic factor residual disease? Q2: Differences
More informationOVARIAN CANCER CLINICAL TRIALS
OVARIAN CANCER CLINICAL TRIALS FRONT-LINE THERAPIES STG III, IV PHASE 3 GOG 3015/Roche YO39523 (16-2745) Carbo/Taxol/Bev/Atezolizumab ECOG 0-2 Allows for primary cytoreductive surgery or interval debulking
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationOVARIAN CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
1 OVARIAN CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Source: UpToDate 2017, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze (Gynecologic
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationOverview and future horizons of PARP inhibitors in BRCAassociated. Judith Balmaña
Overview and future horizons of PARP inhibitors in BRCAassociated breast cancer Judith Balmaña PARP inhibitors: Mechanism of action Clinical development: Monotherapy In combination with chemotherapy Ongoing
More informationMedical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia
Tunisian Health System: Social Welfare with a Public insurance for all citizens including Indigent persons. (± Additional private insurance) Choice: Public Hospital/Private Clinics (Indigents Public H)
More informationASCO- GYN Abstracts 8/3/2011. Susana Campos, MD, MPH. Boston Mass. Prevention. Maintenance. Recurrent Disease.
ASCO- GYN- 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Boston Mass Prevention Maintenance Recurrent Disease Abstracts 5001: Effect of screening on ovarian cancer mortality in the Prostate,
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationGenetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain
Genetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain Why Would We Consider Genetic Testing in Patients With Ovarian Cancer?
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationHighlights in Ovarian Cancer From the 2017 Society of Gynecologic Oncology Annual Meeting on Women s Cancer
May 2017 Volume 15, Issue 5, Supplement 5 A SPECIAL MEETING REVIEW EDITION Highlights in Ovarian Cancer From the 2017 Society of Gynecologic Oncology Annual Meeting on Women s Cancer A Review of Selected
More informationBEATcc Trial: ENGOT-Cx10 / GEICO 68-C / JGOG1084. GCIG Meeting
BEATcc Trial: ENGOT-Cx10 / GEICO 68-C / JGOG1084 GCIG Meeting Ana Oaknin, MD PhD Head of Gynecologic Cancer Program. Vall d Hebron Institute of Oncology(VHIO). Vall d Hebron University Hospital. GEICO
More informationRANDOMISED PHASE III STUDY OF ERLOTINIB VERSUS OBSERVATION IN PATIENTS WITH NO EVIDENCE OF DISEASE PROGRESSION AFTER FIRST LINE, PLATINUM-BASED
RANDOMISED PHASE III STUDY OF ERLOTINIB VERSUS OBSERVATION IN PATIENTS WITH NO EVIDENCE OF DISEASE PROGRESSION AFTER FIRST LINE, PLATINUM-BASED CHEMOTHERAPY FOR HIGH- RISK STAGE I AND STAGE II-IV OVARIAN
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationOld and new drugs in ovarian cancer
Chirurgia del carcinoma ovarico - nuove strategie Bergamo 5 maggio 2011 Old and new drugs in ovarian cancer C.Sessa IOSI, Bellinzona (CH) HSR, Milan (I) TRABECTEDIN, YONDELIS (ET-743) Background TETRAHYDROISOQUINOLINE
More informationImportanza del test genetico nel carcinoma mammario ed ovarico
Importanza del test genetico nel carcinoma mammario ed ovarico Lorena Incorvaia Azienda Ospedaliera Universitaria Policlinco «P.Giaccone» Palermo UOC Oncologia Medica Ovarian Cancer Breast Cancer The range
More informationbreast and OVARIAN cancer
breast and OVARIAN cancer DR DAVID FENNELLY CONSULTANT MEDICAL ONCOLOGIST ST VINCENT S UNIVERSITY HOSPITAL DUBLIN HOW RELEVANT IS ONCOLOGY IN MEDICINE TODAY? Cancer is the second leading cause of death
More informationNOVITA NEL TRATTAMENTO DELLE NEOPLASIE GINECOLOGICHE: OVAIO
SUPERNOVAE IN ONCOLOGIA Pisa 13-14 Novembre 2015 Domenica Lorusso Gynecologic Oncologic Unit National Cancer Institute-Milan NOVITA NEL TRATTAMENTO DELLE NEOPLASIE GINECOLOGICHE: OVAIO % of Patients Surviving
More informationMÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO. Dra. Ruth Vera Complejo Hospitalario de Navarra
MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO Dra. Ruth Vera Complejo Hospitalario de Navarra GOALS Prolongation of survival Cure Improving tumour-related symptoms Stopping tumour progression
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationAvastin NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. bevacizumab (rch)
NAME OF THE MEDICINE Avastin bevacizumab (rch) CAS 216974-75-3 Bevacizumab is an immunoglobulin G (IgG) composed of two identical light chains, consisting of 214 amino acid residues and two 453 residue
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationMedia Release. Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer. Basel, 08 February 2011
Media Release Basel, 08 February 2011 Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer Avastin study in recurrent, platinum-sensitive ovarian cancer showed women lived
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationTrial record 1 of 1 for:
Find Studies About Studies Submit Studies Resources About Site Trial record 1 of 1 for: YO39523 Previous Study Return to List Next Study A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel,
More informationLo stato dell arte nel carcinoma ovarico: Il Trattamento Medico
Azienda Ospedaliera Universitaria Policlinco «P.Giaccone» Palermo UOC Oncologia Medica Direttore Prof. Antonio Russo Lo stato dell arte nel carcinoma ovarico: Il Trattamento Medico Lorena Incorvaia Dichiarazione
More informationExpert Call Innovation in Ovarian Cancer Hosted by John Sonnier, William Blair. December 13, 2016
Expert Call Innovation in Ovarian Cancer Hosted by John Sonnier, William Blair December 13, 2016 1 Forward-Looking Statements This presentation includes forward-looking statements based on management's
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationBackground. TAP, Paclitaxel + Doxorubicin + Cisplatin
A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA; stage
More information